Impact Biomedical (IBO) Interest & Investment Income (2022 - 2026)
Impact Biomedical's (IBO) quarterly Interest & Investment Income came in at $5000.0 in Q1 2026, up 66.67% YoY from $3000.0 in Q1 2025, and up 66.67% on a QoQ basis from $3000.0 in Q1 2025.
Impact Biomedical (IBO) Interest & Investment Income (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Interest & Investment Income data on file, last reported at $5000.0 in Q1 2026.
- Quarterly Interest & Investment Income rose 66.67% year-over-year to $5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14000.0 (up 16.67% YoY) and the FY2023 annual result came in at $13000.0, down 45.83% from the prior year.
- Interest & Investment Income grew to $5000.0 in Q1 2026, from $3000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $90000.0 in Q2 2022 to a low of -$80000.0 in Q4 2022.
- A 5-year average of $3545.5 and a median of $3000.0 in 2022 frame the typical range for Interest & Investment Income.
- The widest YoY moves for Interest & Investment Income: up 103.75% in 2023, down 96.67% in 2023.
- Tracing IBO's Interest & Investment Income over 5 years: stood at -$80000.0 in 2022, then soared by 103.75% to $3000.0 in 2023, then changed by 0.0% to $3000.0 in 2024, then changed by 0.0% to $3000.0 in 2025, then soared by 66.67% to $5000.0 in 2026.
- The last three Interest & Investment Income figures came in at $5000.0 (Q1 2026), $3000.0 (Q1 2025), and $3000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | 2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2,000.00 |
| Mar 31, 2026 | 5,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | 3,000.00 |
| Jun 30, 2023 | 3,000.00 |
| Mar 31, 2023 | 3,000.00 |
| Dec 31, 2022 | -80,000.00 |
| Sep 30, 2022 | 3,000.00 |
| Jun 30, 2022 | 90,000.00 |